Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14415956 | 0.96 | FAAH (0.43) | FAAHRAB9AHPGDMCL1NPC1 | |
| SCHEMBL12518801 | 0.93 | MEN1 (0.42) | FAAHRAB9AHPGDMCL1NPC1 | |
| SCHEMBL12518793 | 0.93 | MEN1 (0.42) | FAAHRAB9AHPGDMCL1NPC1 | |
| SCHEMBL12518794 | 0.93 | MEN1 (0.42) | FAAHRAB9AHPGDMCL1NPC1 | |
| SCHEMBL30610964 | 0.88 | ALDH1A1 (0.43) | FAAHRAB9AHPGDMCL1NPC1 | |
| SCHEMBL24271760 | 0.86 | NAMPT (0.38) | FAAHRAB9AHPGDMCL1NPC1 | |
| SCHEMBL22678184 | 0.86 | MCL1 (0.42) | FAAHMCL1LMNATSHRRECQL | |
| SCHEMBL22199403 | 0.86 | GLP1R (0.41) | FAAHRAB9AHPGDMCL1NPC1 | |
| SCHEMBL20013680 | 0.86 | NAMPT (0.38) | FAAHRAB9AHPGDMCL1NPC1 | |
| SCHEMBL23173478 | 0.84 | TSHR (0.35) | FAAHTSHRRECQLCES2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8632753-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2014-01-21 | — | — | US | disclosed |
| US-20110286929-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2011-11-24 | — | — | US | disclosed |
| US-7854919-B2 | Multivalent constructs for therapeutic and diagnostic applications | Bracco, Suisse SA (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20070243139-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243139-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | FAAH 4572/4885RAB9A 2263/4885HPGD 4588/4885 |
| US-20110286929-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | FAAH 4572/4885RAB9A 2263/4885HPGD 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.